This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HCA Healthcare's (HCA) Q4 Earnings Top Estimates, Surge Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings rise on the back of robust same facility admissions.
Get Explosive Returns with the Filtered Zacks Rank 5 Strategy
by Benjamin Rains
Today we are going to show investors how to add two relatively simple filters to our Zacks Rank #1 criteria that narrows down the number of stocks and often increases its performance as well.
What's in the Cards for Anthem (ANTM) This Earnings Season?
by Zacks Equity Research
Anthem (ANTM) is likely to gain from Q4 results on revenue and membership growth, partly offset by higher expenses.
The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston
Is a Beat in Store for HCA Healthcare (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare (HCA) is likely to gain from higher admissions in Q4 earnings.
What Makes Molina (MOH) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Molina (MOH) have what it takes to be a top stock pick for momentum investors? Let's find out.
MOH vs. JYNT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MOH vs. JYNT: Which Stock Is the Better Value Option?
6 Stocks to Prepare for a Global Economic Slowdown
by Swarup Gupta
A slowdown in Europe and the ongoing trade conflicts have been cited as the major reasons for the IMF's projection cuts.
Will Molina Healthcare Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Molina Healthcare, Inc (MOH).
Molina (MOH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Molina (MOH) closed at $137.13 in the latest trading session, marking a +1.28% move from the prior day.
Will Molina (MOH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Molina (MOH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Weakness Seen in Select Medical Holdings (SEM) Estimates: Should You Stay Away?
by Zacks Equity Research
Select Medical Holdings (SEM) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Has Molina Healthcare (MOH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MOH) Outperforming Other Medical Stocks This Year?
DXC Technology to Buy Luxoft to Expand Digital Business
by Zacks Equity Research
DXC Technology (DXC) aims to expedite the digital transformation journey across its clients and strengthen Digital Solutions business with the acquisition of Luxoft.
Molina Healthcare (MOH) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
Molina Healthcare (MOH) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Molina Renews Pact With CVS to Boost PBM Service Platform
by Zacks Equity Research
Molina (MOH) expands deal with CVS Caremark for Pharmacy Benefit Management services.
Ensign Group's (ENSG) Buyout to Expand Business in Utah
by Zacks Equity Research
Ensign Group (ENSG) acquires the real estate and operations of Bella Terra Cedar City to bolster its growth profile.
Anthem or Humana: Which HMO Stock is a Better Buy for 2019?
by Zacks Equity Research
The health insurance industry is poised for growth despite some policy disturbances; here we analyze which stock Anthem or Humana would provide greater returns in 2019.
Should Value Investors Buy Molina (MOH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tenet (THC) Signs Deal to Provide Services to Cigna Members
by Zacks Equity Research
Tenet (THC) enters new agreements to provide in-network access to Cigna members
Which Stock to Emulate HCA Healthcare (HCA) Success in 2019?
by Zacks Equity Research
While HCA Healthcare (HCA) has been a runaway winner this year, other companies by virtue of strong operating fundamentals are poised for growth in 2019.
The Zacks Analyst Blog Highlights: Computer Programs and Systems, BioTelemetry, HMS, Amedisys and Molina Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Computer Programs and Systems, BioTelemetry, HMS, Amedisys and Molina Healthcare
5 Great Healthcare Stocks to Buy for 2019
by Swarup Gupta
Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.
Centene Unit Collaborates With RxAdvance for New PBM Platform
by Zacks Equity Research
Centene's (CNC) Mississippi unit partners RxAdvance for establishing a transformative pharmacy benefit management model.
4 HMOs Likely to Cruise Ahead of Industry in 2019
by Sapna Bagaria
Players in the HMO industry should gain from aging population, expanding government business, technological investment and industry consolidation